Clinical trial / 2017
Infliximab combined with a plant-based diet induced high remission rates at 6 weeks in biologic-naïve patients with Crohn disease.
Biologic-naïve patients with Crohn disease received standard infliximab induction along with a lacto-ovo-semivegetarian diet during hospitalization. Two adults were withdrawn due to intestinal obstruction. Intention-to-treat and per-protocol remission rates at week 6 were 96% (44/46) and 100% (44/44), respectively. Mean CDAI score dropped from 314 on admission to 63 at week 6 (p < 0.0001), mean CRP decreased from 5.3 mg/dL to 0.2 mg/dL (p < 0.0001), and mucosal healing was achieved in 46% (19/41) of cases.
- Study type
- Prospective single-group trial
- Who was studied
- 46 patients with Crohn disease naïve to biologics (26 newly diagnosed adults, 11 newly diagnosed children, 9 relapsing adults)
- What was measured
- Remission at week 6, CDAI score, CRP concentration, and mucosal healing
THE PAPER
Induction with Infliximab and a Plant-Based Diet as First-Line (IPF) Therapy for Crohn Disease: A Single-Group Trial.
Chiba M, Tsuji T, Nakane K, Tsuda S, Ishii H, Ohno H, Watanabe K, Ito M, Komatsu M, Sugawara T. Perm J, 2017.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.